Medical devices, healthcare technology and the business of care
510(k) clearance · K261929

Upper Arm Blood pressure monitor (BP7155D)

OMRON Healthcare, Inc. · Decision date Sep 10, 2026

MEDTECHLEDGER EXPLANATIONK261929

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on September 10, 2026 for K261929, an upper arm blood pressure monitor submitted by OMRON Healthcare, Inc. of Hoffman Estates, Illinois. The device is listed as the Upper Arm Blood pressure monitor (BP7155D) under regulation number 870.1130, product code DXN, in the Cardiovascular specialty; the application was received June 9, 2026. SESE in a 510(k) pathway denotes clearance to market, not premarket approval of the device.

The FDA review document describes the Omron BP7155D as a battery-powered, non-invasive upper arm monitor intended for over-the-counter home use, measuring systolic pressure, and states that the proposed device incorporates Bluetooth Low Energy to transmit stored blood pressure and pulse data to external devices. The record does not include the full intended-use statement, measurement ranges or accuracy data, so performance characteristics remain unknown from this source.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Sep 10, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261929
Regulatory pathway
510(k) premarket notification
Product code
DXN
Decision code
SESE
Decision date
Sep 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, Measurement, Blood-Pressure, Non-Invasive.

Product code
DXN
FDA device class
2

FDA decision timeline

  1. K261929 received

    Application receipt date recorded by FDA.

  2. K261929 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code DXN

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

OMRON Healthcare, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Hoffman Estates, IL

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records